第47届圣安东尼奥乳腺癌研讨会（SABCS）将于当地时间2024年12月10日至13日在美国得克萨斯州圣安东尼奥举行。SABCS是全球最大的乳腺癌领域盛会，来自102个国家的超过1万名注册参会者将在为期四天的会议中展示1886篇被接受的论文摘要。肿瘤瞭望特别整理中国专家被收录的壁报内容，以飨读者。
编者按：第47届圣安东尼奥乳腺癌研讨会（SABCS）将于当地时间2024年12月10日至13日在美国得克萨斯州圣安东尼奥举行。SABCS是全球最大的乳腺癌领域盛会，来自102个国家的超过1万名注册参会者将在为期四天的会议中展示1886篇被接受的论文摘要。肿瘤瞭望特别整理中国专家被收录的壁报内容，以飨读者。（注：因官网未公布详细作者单位，如有遗漏或错误，欢迎留言指正。）
Poster Session 1
日期：12月11日
时间：12:30～2:00 p.m
地点：Halls 2-3
P1-01-04：EPLIN and EPLIN responsive protein APOC3 in breast cancer
EPLIN及其应答蛋白APOC3在乳腺癌中的作用
报告作者：Cai Wang
P1-02-12:Prospective phase II study on the efficacy and safety of hetrombopag for the treatment of cancer therapy-induced thrombocytopenia in patients with breast cancer
在乳腺癌患者中应用海曲泊帕治疗癌症治疗诱导的血小板减少症的有效性和安全性的前瞻性II期研究
报告作者：Hanfang Jiang
P1-02-18:Cancer-Associated Fibroblast-Mediated Suppression of T Cell Activity as a mechanism of Resistance to Immunoradiotherapy in Breast Cancer
癌症相关成纤维细胞介导的T细胞活性抑制作为乳腺癌免疫放疗抵抗的机制
报告作者：Rongrong Wu
P1-04-04:evelopment and validation of a nomogram for axillary lymph node metastasis risk in breast cancer
乳腺癌腋窝淋巴结转移风险列线图的建立和验证
报告作者：Xiaoyun Mao
P1-04-12:Optimizing Tolerability of Pyrotinib in HER2-Positive EarlyStage High-Risk Breast Cancer:A Multicenter，Randomized，ThreeCohort Study
优化吡咯替尼治疗HER2阳性早期高危乳腺癌的耐受性：一项多中心、随机、三队列研究
报告作者：Qiao Cheng
P1-04-22:Loss of SMAD4 Drives Breast Cancer Invasion and Metastasis through E2F1-Mediated Activation of the PEG10-ERK Axis
SMAD4缺失通过E2F1介导的PEG10-ERK轴激活驱动乳腺癌的侵袭和转移
报告作者：Dan Shu
P1-04-25:Fast and accurate detection of tumor-immune cell interactions with deep learning
利用深度学习快速准确地检测肿瘤-免疫细胞相互作用
报告作者：Huiping Liu
P1-05-07:Expression of ATP6AP2 in clinical breast cancer and the prognostic and therapeutic value in ERBB2 subtype of breast cancer
ATP6AP2在临床乳腺癌中的表达及其在ERBB2亚型乳腺癌中的预后和治疗价值
报告作者：Jia Tong
P1-05-24:Biomarkers and Spatial Determinants of SHR-A1811 Efficacy in Neoadjuvant Treatment for HER2-Positive Breast Cancer
SHR-A1811在HER2阳性乳腺癌新辅助治疗中疗效的生物标志物和空间决定因素
报告作者：Zhi-Ming Shao
P1-05-27:Analytical comparison of tissue-based next-generation sequencing assays for the detection of PIK3CA，AKT1，and PTEN tumor alterations in breast cancer
基于组织的二代测序检测乳腺癌中PIK3CA、AKT1和PTEN肿瘤改变的分析比较
报告作者：Xiaodun Li
P1-06-04:Psychological stress and its correlations to patients with acute lymphedema after breast cancer surgery
心理应激与乳腺癌术后急性淋巴水肿的相关性研究
报告作者：Li-Chen Tang
P1-06-06:Oral cyclophosphamide-induced hemorrhagic cystitis from metronomic Cyclophosphamide/Methotrexate/5-Fluorouracil for treatment of synchronous bilateral breast cancer–A case report
口服环磷酰胺导致出血性膀胱炎：一例应用节拍化疗方案环磷酰胺/甲氨蝶呤/5-氟尿嘧啶治疗同期双侧乳腺癌的病例报告
报告作者：Jina Yun
P1-06-24:Single-cell RNA sequencing reveals the role of HSPA1B+immune cells in breast cancer microenvironment remodeling during neoadjuvant chemotherapy
单细胞RNA测序揭示HSPA1B+免疫细胞在乳腺癌新辅助化疗微环境重塑中的作用
报告作者：Zihan Zhai
P1-06-29:Targeting NRP1 reduces triple-negative breast cancer lung metastasis and improves immunotherapy efficacy
靶向NRP1可降低三阴性乳腺癌肺转移，并提高免疫治疗疗效
报告作者：Zhuxi Duan
P1-07-20:Mechanism of miR-221-3p/PARP1 regulating the progression of triple-negative breast cancer through the NF-κB pathway
miR-221-3p/PARP1通过NF-κB通路调控三阴性乳腺癌进展的机制
报告作者：Qianqian Lei
P1-07-21:Efficacy of CDK4/6 Inhibitor Abemaciclib in Metastatic Triple-Negative Breast Cancer
CDK4/6抑制剂阿贝西利治疗转移性三阴性乳腺癌的疗效
报告作者：Chuling Zhuang
P1-07-25:E3 ubiquitin-protein ligase RNF40 promotes triplenegative breast cancer progression and metastasis by promoting TRIM28 expression and stabilizing TWIST1 protein
E3泛素蛋白连接酶RNF40通过促进TRIM28表达和稳定TWIST1蛋白促进三阴性乳腺癌的进展和转移
报告作者：Junjiang Fu
P1-07-28:Real-World Study on Efficacy and Safety of SG Alone and Combined with Immunotherapy in Metastatic Triple Negative Breast Cancer Patients
SG单药及联合免疫治疗转移性三阴性乳腺癌患者的疗效和安全性的真实世界研究
报告作者：Jianli Zhao
P1-08-02:HIF-1-dependent expression of integrinβ3 incorporated into extracellular vesicles promotes metastasis of breast cancer cells to the brain
HIF-1依赖的整合素β3表达整合入细胞外囊泡中，促进乳腺癌细胞向脑的转移
报告作者：Yongkang Yang
P1-08-05:The mechanism of FOXO3a in coping with oxidative stress to promote TNBC progression
FOXO3a应对氧化应激促进TNBC进展的机制
报告作者：Manqing Cao
P1-08-21:Synchronous female breast cancer and follicular lymphoma in a single patient:A case report
女性乳腺癌同时合并滤泡性淋巴瘤一例报告
报告作者：Zijun Zhao
P1-09-05:Simultaneous 3D Mapping of RNA and Protein to Advance Personalized Medicine in Breast Cancer
同时进行RNA和蛋白质的3D绘图以推进乳腺癌的个体化治疗
报告作者：Yue Li
P1-09-11:Machine Learning based analysis in chemotherapy resistant triple negative breast cancer
基于机器学习的化疗耐药三阴性乳腺癌分析
报告作者：Dongling Wu
P1-09-24:Cancer cell-derived exosomal miR-20a-5p inhibits CD8+T-cell function and confers anti-programmed cell death 1 therapy resistance in triple-negative breast cancer
三阴性乳腺癌细胞衍生的外泌体miR-20a-5p抑制CD8+T细胞功能并导致抗程序性细胞死亡1治疗耐药
报告作者：XIANGDONG BAI
P1-10-17:HER2+breast cancer diagnosed in the 2nd trimester of pregnancy
妊娠中期诊断的HER2+乳腺癌
报告作者：Shiliang Zhang
P1-11-01:Immune Infiltration Correlates with Transcriptomic Subtypes in Primary ER+Invasive Lobular Breast Cancer
原发性ER+浸润性小叶乳腺癌的免疫浸润与转录组亚型相关
报告作者：Fangyuan Chen
P1-11-07:Associations between Breast Cancer Index Classifications and MSK-IMPACT Genomic Profiles in HR+/HER2-Breast Cancer
HR+/HER2-乳腺癌中乳腺癌指数分类与MSK-IMPACT基因组谱的相关性
报告作者：Hong Zhang
P1-11-11:Pathological Complete Response and Survival Outcomes ofSingle Hormone Receptor-Positive/HER2-Negative Breast Cancer after Neoadjuvant Treatment and Further analysis of its Intrinsic Biological Features and Immune Landscape.
新辅助治疗后单激素受体阳性/HER2阴性乳腺癌的病理完全缓解及生存结局，以及对其内在生物学特征和免疫图谱的进一步分析
报告作者：Lei Ji
P1-11-12:Early-stage HR+/HER2-breast cancer patients under 50 years old with a low-risk identified by the 70-gene signature(MammaPrintTM)could benefit from ovarian function suppression:A real-world study in China.
基于70基因特征（MammaPrintTM）鉴定为低风险的50岁以下早期HR+/HER2-乳腺癌患者可从卵巢功能抑制中获益：一项中国真实世界研究
报告作者：Weijuan Jia
P1-11-13:Development and Validation of a Deep Learning Model for HR+/HER2-Early-stage Breast Cancer Recurrence Prediction(HERPAI)using Conventional Clinical and Pathological Data:A Realworld Study in Chinese Population
基于常规临床和病理数据构建并验证用于HR+/HER2-早期乳腺癌复发预测的深度学习模型（HERPAI）：一项针对中国人群的真实世界研究
报告作者：Ruixin Pan
P1-12-09:Real-world prescribing patterns and outcomes of CDK4/6 inhibitors in elderly patients with metastatic HR+/HER2-breast cancer
CDK4/6抑制剂在老年转移性HR+/HER2-乳腺癌患者中的真实世界处方模式和结局
报告作者：Xiao-Wei Tan
P1-12-26:Clinical Case Vignette-Molecular PET Imaging to Guide Selection for Endocrine Therapy in Estrogen-Receptor Positive Metastatic Breast Cancer
临床病例简述——分子PET成像指导雌激素受体阳性转移性乳腺癌内分泌治疗的选择
报告作者：Wenhui Zhou
P1-12-27:Clinical Case Vignette:Estrogen Receptor Targeting PET Imaging to Monitor Treatment Response to Endocrine Therapy in Lobular Breast Cancer
临床病例简述：雌激素受体靶向PET显像监测乳腺小叶癌内分泌治疗的疗效
报告作者：Wenhui Zhou
京公网安备 11010502033352号